Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYT0OG)

Drug Name

Vigabatrin Drug Info

Synonyms

GVG; Sabril; Sabrilex; Vigabatrina; Vigabatrine; Vigabatrinum; Aventis Brand of Vigabatrin; Gamma Vinyl GABA; Gamma Vinyl gamma Aminobutyric Acid; Hoechst Brand of Vigabatrin; Vigabatrin Aventis Brand; Vigabatrin Hoechst Brand; Vigabatrin Yamanouchi Brand; Vigabatrina [Spanish]; Vigabatrine [French]; Vigabatrinum [Latin]; Yamanouchi Brand of Vigabatrin; M071754; MDL 71754; RMI 71754; V 8261; V8261_SIGMA; CPP-109; Gamma-Vinyl GABA; MDL 71,754; MDL-71754; RMI-71754; RMI-71890; Sabril (TN); Sabrilex (TN); Gamma-Vinyl-GABA; Hexenoic acid, 4-amino; Vigabatrin [USAN:BAN:INN]; Vigabatrin [USAN:INN:BAN]; Gamma-Vinyl-gamma-Aminobutyric Acid; Gamma-Vinyl-gamma-aminobutyric acid; Vigabatrin (JAN/USAN/INN); Acid, gamma-Vinyl-gamma-Aminobutyric; (R,S)-4-Amino-5-hexenoic acid; (inverted question mark)-gamma-Vinyl GABA; 4-Amino-5-hexenoic acid; 4-Aminohexenoic acid; 4-aminohex-5-enoic acid

Indication

Disease Entry	ICD 11	Status	REF
Alcohol dependence	6C40.2	Approved	[1]
Cocaine addiction	6C45.2	Approved	[1]
Complex partial seizure	8A68.0	Approved	[2]
Epilepsy	8A60-8A68	Approved	[2]
Infantile spasm	8A62.0	Approved	[2]
West syndrome		Approved	[1]

Therapeutic Class

Anticonvulsants

Cross-matching ID

PubChem CID: 5665
ChEBI ID: CHEBI:63638
CAS Number: CAS 68506-86-5
TTD Drug ID: DMYT0OG
VARIDT Drug ID: DR00270
ACDINA Drug ID: D00727

Molecule-Related Drug Atlas

Molecule Type:

DTT

DTP

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting GABA transaminase (ABAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Alanine	DMZDN4W	Dietary shortage	5B5K	Approved	[5]
Pyridoxal Phosphate	DMO2K0J	Malnutrition	5B50-5B71	Approved	[5]
Pyruvic acid	DM7Q41G	Malnutrition	5B50-5B71	Approved	[5]
Divalproex sodium	DM4RK0G	Seizure disorder	8A6Z	Approved	[5]
CPP-115	DMK9NQI	Tourette syndrome	8A05.00	Phase 2	[6]
K-828-AB	DMJLNZQ	Dementia	6D80-6D86	Phase 2	[7]
CPP -15	DMQCHU3	Infantile spasm	8A62.0	Phase 1	[6]
T83193	DMHO29Y	Discovery agent	N.A.	Patented	[8]
4-hydroxybenzaldehyde	DM471P5	Discovery agent	N.A.	Patented	[9]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By Proton-coupled amino acid transporter 1 (SLC36A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glycine	DMIOZ29	Allergic rhinitis	CA08.0	Approved	[11]
L-Proline	DMKSTWR	Malnutrition	5B50-5B71	Approved	[12]
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[13]
Aminolevulinic acid hci	DMS4BLQ	Acne vulgaris	ED80	Approved	[14]
Gaboxadol	DMI53FU	Insomnia	7A00-7A0Z	Approved	[15]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GABA transaminase (ABAT)	TTT2LD9	GABT_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Proton-coupled amino acid transporter 1 (SLC36A1)	DT48WEM	S36A1_HUMAN	Substrate	[4]

------------------------------------------------------------------------------------

References

1	Vigabatrin FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4821).
3	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
4	Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats. Pharm Res. 2012 Apr;29(4):1134-42.
5	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
6	Clinical pipeline report, company report or official report of Catalyst Pharma.
7	Phase II clinical trial of K-828-AB for treating behavioral and psychological symptoms of dementia. Kowa Co. Ltd.
8	Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5.
9	Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl)propan-1-one. Bioorg Med Chem Lett. 2009 Feb 1;19(3):731-4.
10	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
11	Transport of amino acids and GABA analogues via the human proton-coupled amino acid transporter, hPAT1: characterization of conditions for affinity and transport experiments in Caco-2 cells. Eur J Pharm Sci. 2008 Sep 2;35(1-2):86-95.
12	PAT1 (SLC36A1) shows nuclear localization and affects growth of smooth muscle cells from rats. Am J Physiol Endocrinol Metab. 2014 Jan 1;306(1):E65-74.
13	Indirect regulation of the intestinal H+-coupled amino acid transporter hPAT1 (SLC36A1). J Cell Physiol. 2005 Aug;204(2):604-13.
14	Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1). Br J Pharmacol. 2010 Mar;159(6):1339-53.
15	Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan. Br J Pharmacol. 2009 Aug;157(8):1380-9.